Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 2/20 | 0.59 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | BCL6 | P41182 | 1/20 | 0.53 |
| ▸ | BCOR | Q6W2J9 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17194149 | 0.87 | VCAM1 (0.54) | RECQLVCAM1MAPTBCL6BCOR | |
| SCHEMBL10617330 | 0.86 | BCL6 (0.63) | RECQLVCAM1MAPTBCL6BCOR | |
| SCHEMBL9349737 | 0.83 | VCAM1 (0.58) | RECQLVCAM1MAPTBCL6BCOR | |
| SCHEMBL29060813 | 0.83 | VCAM1 (0.58) | RECQLVCAM1MAPTBCL6BCOR | |
| SCHEMBL29000056 | 0.83 | VCAM1 (0.58) | RECQLVCAM1MAPTBCL6BCOR | |
| SCHEMBL11291067 | 0.82 | VCAM1 (0.57) | RECQLVCAM1MAPTBCL6BCOR | |
| SCHEMBL2336518 | 0.81 | RECQL (0.68) | RECQLVCAM1MAPTBCL6BCOR | |
| SCHEMBL1465485 | 0.80 | MAPT (0.50) | RECQLVCAM1MAPTALDH1A1LMNA | |
| SCHEMBL6067789 | 0.78 | MAPT (0.62) | RECQLVCAM1MAPTBCL6BCOR | |
| SCHEMBL73860 | 0.78 | VCAM1 (0.70) | RECQLVCAM1MAPTBCL6BCOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259880-A1 | THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-08 | — | — | US | disclosed |
| US-5865856-A | MIXTURE CONTAINING COUPLER AND DEVELOPER | WELLA AKTIENGESELLSCHAFT (DE) | 1999-02-02 | — | — | US | disclosed |
| EP-0797980-A1 | Oxidation hair dye composition comprising a 2,5-diaminobenzonitrile as well as 2,5-diaminobenzonitrile compounds | Wella Aktiengesellschaft (DE) | 1997-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259880-A1 | THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF | DPP4, DPP7, DPP3 | RECQL 3913/4885VCAM1 2520/4885MAPT 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.